echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Lilly and Hehuang Sinopharm carry out R & D and operation cooperation of tumor drugs in China

    Lilly and Hehuang Sinopharm carry out R & D and operation cooperation of tumor drugs in China

    • Last Update: 2013-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: on October 10, 2013, US pharmaceutical giant Lilly signed an agreement with Chi med of China to jointly develop and operate a drug for treating several tumors Lilly will work with Hutchison Whampoa pharmaceutical, which is a research and development focus of Hutchison Whampoa pharmaceutical, to develop furquitinib (hmpl-013), a small molecule drug that inhibits the tyrosine kinase of vascular endothelial growth factor (VEGF) receptor The potential of this drug in the treatment of advanced refractory solid tumors has been confirmed in phase I clinical trials, and a follow-up phase II clinical study is in progress Several phase II and phase III clinical studies will study the efficacy of fiquitinib in the treatment of various solid tumor patients The agreement includes a series of payments, including $86.5 million from Lilly to Hehuang pharmaceutical, including upfront fees and mileage fees If fiquitini is commercialized in China, Hutchison Whampoa will also receive a tiered royalty The two companies will share the cost of future development, although further research will be carried out by Hutchison alone in China Lilly has experienced the development of VEGF inhibition Recently, the phase III clinical trial of ramucirumab in the treatment of breast cancer was disappointing, but it was positive in the gastric cancer test He Jun, CEO of Huang Zhonghua pharmaceutical technology, didn't talk about the potential of furaquinidine in detail, but he said it is a promising drug for treating various tumors "We believe that furoquinone is potentially active in many high incidence rate tumors, and may benefit patients who are significantly unsatisfied with China's medical needs," he added "This cooperation with Lilly will consider the development of various forms of cancer in China, which is much faster than our own development." In recent years, Lilly has increased its investment in China, including the establishment of a diabetes research and development center in Shanghai in June 2012 Like diabetes, cancer is another chronic disease with increasing incidence rate in China Lilly expects to benefit from the development of furoquinone "In Lilly's emerging markets business, our focus is on delivering innovative drugs to patients from our R & D line and through partnerships with respected scientific companies such as HMP," said Jacques Tapiero, senior vice president and emerging markets president of Lilly "Together, we are committed to helping cancer patients in China meet their medical needs."
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.